Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
62.3M
-
Number of holders
-
61
-
Total 13F shares, excl. options
-
44M
-
Shares change
-
+18.1M
-
Total reported value, excl. options
-
$226M
-
Value change
-
+$110M
-
Number of buys
-
48
-
Number of sells
-
-15
-
Price
-
$5.13
Significant Holders of Elevation Oncology, Inc. - Common stock, par value $0.0001 per share (ELEV) as of Q1 2024
68 filings reported holding ELEV - Elevation Oncology, Inc. - Common stock, par value $0.0001 per share as of Q1 2024.
Elevation Oncology, Inc. - Common stock, par value $0.0001 per share (ELEV) has 61 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 44M shares
of 62.3M outstanding shares and own 70.55% of the company stock.
Largest 10 shareholders include FARALLON CAPITAL MANAGEMENT LLC (3.89M shares), Point72 Asset Management, L.P. (3.37M shares), TANG CAPITAL MANAGEMENT LLC (3.06M shares), Balyasny Asset Management L.P. (3.06M shares), Aisling Capital Management LP (2.83M shares), venBio Partners LLC (2.7M shares), BRAIDWELL LP (2.38M shares), Darwin Global Management, Ltd. (2.33M shares), BVF INC/IL (2.31M shares), and CITADEL ADVISORS LLC (1.57M shares).
This table shows the top 61 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.